ArticleIn silico pharmacology2026
Piceid as a promising candidate for multi-target adjunctive therapeutic for inflammation-associated cervical cancer progression: an in silico approach.
Article in In silico pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 7-Deshydroxypyrogallin-4-carboxylic acid dietary phytochemical as a putative FTO inhibitor in breast cancer: an integrated computational and cytotoxicity study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting the HPV E6-p53 degradation axis via computational andFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major global health challenge, as persistent high-risk human papillomavirus (HPV) infection along with chronic inflammation is one of the primary drivers that allows progression of cervical cancer. Despite recent advances in treatment strategies, there are still a lack of effective multi-target therapies that will modulate inflammatory, apoptotic and immune-regulatory pathways simultaneously. The originality of this study lies in conducting a comprehensive evaluation of piceid, as a multi-target immune-modulatory agent for cervical cancer focusing on molecular networks associated with inflammation. An integrated computational and experimental system was utilized to evaluate the potential therapeutic activity of piceid against molecular targets associated with cervical cancer. Molecular docking, MM-GBSA binding free energy calculations, molecular dynamics simulation for stability assessment of the complexes, ADMET profiling for estimating pharmacokinetic and toxic properties, and density functional theory (DFT) to assess electronic and chemical reactivity properties were all conducted in silico. In vitro validation of results was conducted using an MTT cell viability assay. Molecular docking revealed favorable binding of piceid to all five cervical cancer associated targets, with strongest affinity toward TGFBR2 (- 6.530 kcal/mol) and CASP8 (- 5.873 kcal/mol) which was further confirmed using MM-GBSA analysis. Molecular dynamics simulations (200 ns) demonstrated stable and flexible piceid-CASP8 and piceid-TGFBR2 complexes, with RMSD stabilization and minimal RMSF fluctuations in binding regions. Density functional theory analysis revealed favorable electronic properties supporting hydrogen bonding and electrostatic interactions. ADMET profiling predicted an overall favorable pharmacokinetic profile. Piceid exhibited dose-dependent cytotoxicity against HeLa cervical cancer cells, inducing marked morphological alterations, although with a higher IC₅₀ than doxorubicin. These findings suggest that piceid may serve as a promising candidate for multi-target immune-modulatory activity to prevent the progress of Cervical Cancer. Grahical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.